Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

The PD-1 Inhibitor Drugs Market is witnessing remarkable growth as immunotherapy revolutionizes cancer treatment. PD-1 inhibitors, a class of checkpoint inhibitors, enhance the immune system’s ability ...

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...

Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, discusses some of the most promising findings from the EPIC-A trial of cemiplimab with chemotherapy in treating locally advanced or metastatic penile ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...